Rare Mutations and Fusions Patient Gateway
About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
RET-Positive Lung Cancer: New Treatments and Beyond
The four-person panel, including John Heymach, MD, PhD, from MD Anderson Cancer Center, discuss the current FDA-approved targeted treatments for RET-positive lung cancer... -
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Sponsors
